NCT05484375View on ClinicalTrials.gov

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2029

Conditions
Metastatic Nasopharyngeal Carcinoma
Interventions
DRUG

Capecitabine plus toripalimab

Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks

All Listed Sponsors
collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Hunan Cancer Hospital

OTHER

lead

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

NCT05484375 - Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment | Biotech Hunter | Biotech Hunter